Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;80(2):197-208.
doi: 10.1007/s40265-020-01260-9.

Dulaglutide: A Review in Type 2 Diabetes

Lesley J Scott  1
Affiliations
Review

Dulaglutide: A Review in Type 2 Diabetes

Lesley J Scott. Drugs. 2020 Feb.

Abstract

Subcutaneous dulaglutide (Trulicity®) is a once-weekly glucagon-like peptide-1 receptor agonist that is approved in numerous countries as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes (T2D). In the clinical trial and real-world settings, once-weekly subcutaneous dulaglutide, as monotherapy or add-on therapy to other antihyperglycaemic agents (including oral antihyperglycaemic drugs and insulin), was an effective and generally well tolerated treatment in adults with inadequately controlled T2D, including in high-risk patients [e.g. obese and elderly patients, those with stage 3 or 4 chronic kidney disease (CKD) and/or cardiovascular (CV) disease]. In the REWIND CV outcomes trial in patients with T2D with or without CV disease, dulaglutide was associated with a significant reduction in the risk of a major adverse cardiac event (MACE; primary composite outcome comprising CV death, nonfatal myocardial infarction or nonfatal stroke) at a median of 5.4 years' follow-up. Given its durable glycaemic efficacy, beneficial effects on bodyweight and MACE outcomes, low inherent risk of hypoglycaemia and convenient once-weekly regimen, dulaglutide remains an important option in the management of T2D.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Diabetes Ther. 2019 Jun;10(3):1067-1088 - PubMed
    1. BMJ Open Diabetes Res Care. 2019 Dec 9;7(1):e000884 - PubMed
    1. Diabetes Obes Metab. 2019 Nov;21(11):2570-2575 - PubMed
    1. Curr Med Res Opin. 2019 May;35(5):893-901 - PubMed
    1. Hypertension. 2014 Oct;64(4):731-7 - PubMed

MeSH terms

LinkOut - more resources

  NODES
admin 4
twitter 2